A former world champion middle-distance runner from Belarus has been temporarily suspended for doping after testing positive for a drug that has been in clinical trials to treat muscle wasting.
The Athletics Integrity Unit (AIU) said on August 27 that 31-year-old Marina Arzamasova has been notified of the allegation, one month before the world championships in Qatar.
The AIU was formed by the International Association of Athletics Federations (IAAF) in April 2017 to combat doping in the sport of athletics.
Arzamasova's case involves LGD-4033, better known as Ligandrol, the AIU said. Ligandrol is reportedly used in supplements by body builders to build muscle mass with fewer side effects than steroids.
Arzamasova won the 800 meters at the 2015 world championships in Beijing and was European champion in 2014. She placed seventh at the 2016 Rio de Janeiro Olympics.
The AIU operates fully independently from the IAAF.
Editors' Picks
Top Trending
1
UEFA To Rule After Kosovar Players Walk Off In Romania Amid Claims Of 'Racist' Chants
2U.S. Reportedly Allows Ukraine To Strike Russia With Long-Range Weapons
3Attack From Afghanistan Kills Chinese National In Tajikistan, Sources Say
4No Smooth Sailing For Climate Activist Greta Thunberg In The Caucasus
5Could U.S. Long-Range Missiles Tip The Balance In The Ukraine War?
6A Blood-Red Stripe: Russian Opposition's Anti-War Rally Shadowed In Advance By Controversy Over Flag
7Russian Forces Reportedly Start All-Out Assault On Key Ukrainian City Of Kupyansk
8In Bulgaria, A Secret Russian Consulate Is Unveiled
9Putin Not Interested In Negotiations, Only In Ending His Own Isolation, Zelenskiy Says
10Ukraine Live Briefing: At Least 6 Killed In Latest Russian Strikes
RFE/RL has been declared an "undesirable organization" by the Russian government.
If you are in Russia or the Russia-controlled parts of Ukraine and hold a Russian passport or are a stateless person residing permanently in Russia or the Russia-controlled parts of Ukraine, please note that you could face fines or imprisonment for sharing, liking, commenting on, or saving our content, or for contacting us.
To find out more, click here.